

CIN: L27100TG1989PLC010122 ZENOTECH LABORATORIES LIMITED Registered Office & Factory: Survey No.250 -252 Turkapally Village Shamirpet Mandal Hyderabad - 500 078 T.S., India. Tel: +91 90320 44584/ 585 Email: info@zenotech.co.in www.zenotechlab.com

Date: October 28, 2022

BSE Limited Market Operations Dept., Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001

Scrip Code: 532039

Dear Sir,

Sub: Outcome of the Board Meeting of Zenotech Laboratories Limited (the Company) held today i.e. October 28, 2022

With reference to the intimation of Board Meeting submitted on October 20, 2022, we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. October 28, 2022 which commenced at 5:00 p.m. IST and ended at 7:00 p.m. IST.

The Board has, *inter-alia*, approved Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2022.

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Unaudited Standalone Financial Results of the Company for the quarter and half year ended September 30, 2022 along with the Limited Review Report of the Statutory Auditors.

We request you to take the above on record.

Thanking you,

Yours faithfully, For **Zenotech Laboratories Limited**

Abdul Gafoor Mohammad Company Secretary & Compliance Officer

Encl: as above

Independent Auditor's Review Report on the Quarterly and half yearly Unaudited Financial Results of the Company

Review report to the Board of Directors of Zenotech Laboratories Limited


 We have reviewed the unaudited financial results ("the Statement") of Zenotech Laboratories Limited ("the Company") for the quarter and half year ended 30th September 2022, being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), which has been initialed by us for identification.

2. Management's Responsibility

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

3. Auditor's Responsibility

Our responsibility is to express a conclusion on this Statement based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



PKF SRIDHAR & SANTHANAM LLP

Chartered Accountants

4. Conclusion

Based on our review conducted, as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PKF Sridhar & Santhanam LLP Chartered Accountants Firm Registration No. 0039905/S200018

Viswanadh VNSS Kuchi Partner Membership No. 210789 Place: Hyderabad Date: 28-October-2022 UDIN: 22210789BBDDHR9282



3-225, First Floor, Kavuri Hills road, CBI Colony, Madhapur, Hyderabad-S00033 Telangana Ph:040 48532743/48533743 Head Office/Registered Office • No.91-92 7th Floor • Dr.Radhakrishnan Salai • Mylapore • Chennai • 600004, India Tel +91 44 28112985 • Fax +91 44 28112989 • Email sands@pkfindia.in • www.pkfindia.in PKF SRIDHAR & SANTHANAM LLP is a registered limited liability partnership with LLPIN AAB-6552(Registration No .with ICAI is 0039905/S200018.

	Statement of Standalone Unaudited Financ					ber 2022	_	
_		(Rs in lakhs, except share and per equity share data)						
SL	Particulars	Quarter ended			Half Year ended		Year ended	
No.		30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	31.03.2022	
_		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
	D D D C	007.10	1 101 70	(0(20	0.000.00	1 602 16	2.240.24	
1	Revenue From Operations	927.18	1,134.78	696.20	2,061.96	1,583.46	3,249.37	
П	Other Operating Income	101.82	101.77	101.82	203.59	203.59	407.14	
Ш	Other Income	64,67	4.84	3.05	69.51	10.11	62.93	
IV	Total Income (I+II+III)	1,093.67	1,241.39	801.07	2,335.06	1,797.16	3,719.44	
v	Expenses							
	a). Cost of materials consumed		6.08	0.04	6.08	0.04	0.11	
	b). Purchase of Stock-in-Trade		0.00	0.04	0.06	0.04	9.11	
	c). Changes in inventories of finished goods, work-in-		-					
	progress and stock-in-trade			-	-	-	-	
	d). Employee benefit expenses	192.17	191.67	172.72	383.84	348.61	709,52	
		192.17	105450104			2.03.02.0	10050000	
	e). Finance costs	100 53	11.22	33.40	11.22	79.75	121.52	
	f). Depreciation and amortization expense	180.53	178.60	180.37	359.13	352.80	697.35	
	g). Other Expenses	336.03	329.92	319.91	665.95	571.67	1,200.81	
1.07	Total expenses	708.73	717.49	706.43	1,426.22	1,352.87	2,729.31	
VI	Profit/(Loss) before exceptional items and tax (IV-V)	384.94	523.90	94.64	908.84	444.29	990.13	
VII	Exceptional items	-	-	-		-		
VIII	Profit/(Loss) before tax (VI-VII)	384,94	523.90	94.64	908.84	444.29	990.13	
IX	Tax expense							
	a). Current Tax	- 1	-	-	-		-	
	b). Deferred Tax	108.44	146.84		255.28		(1,227.46	
_	Total Tax Expense (IX)	108.44	146.84	-	255.28		(1,227.46	
X	Profit/(Loss) for the period (VIII-IX)	276.50	377.06	94.64	653.56	444.29	2,217.59	
XI	Other Comprehensive Income							
	a). Items that will not be reclassified to Profit or Loss							
	Re - measurement of the defined benefit obligations	1.40	1.40	(0.14)	2.80	(0.29)	5.60	
	Re - measurement of the defined bencht obligations							
	b). Items that will be reclassified to Profit or Loss		-	-	-	1	-	
	Less: Income Tax	(0.35)	(0.35)	7	(0.70)	-	-	
	Total Comprehensive Income for the period (X+/-XI)	277.55	378.11	94.78	655.65	444.57	2,223.19	
XIII	Paid-up equity share capital (Face value of ₹ 10/- per share)	6,103.06	6,103.06	6,103.06	6,103.06	6,103.06	6,103.06	
XIV	Reserves i.e. Other equity						960.95	
XV	Earnings/ (loss) per share (of ₹ 10/- each) (not annualised)							
	a) Paula	0.45	0.62	0.16	1.07	0.73	3.63	
	a). Basic a) Diluted	0.45	0.62	0.16	1.07	0.73	3.63	



ZENOTECH LABORATORIES LIMITED

	and the second second	Rs in Lak
Particulars	As at	As at
Tarticulars	30 September 2022	31 March 202
	Unaudited	Audited
LOOPTO		
ASSETS		
(1) Non Current Assets	(752 00	= 000
(a) Property, Plant and Equipment	6,753.00	7,090.
(b) Capital Work-In-Progress	28.05	27.
(c) Financial Assets		
(i) Investments		
(ii) Others	111.42	78.
(d) Deferred Tax Assets (net)	972.18	1,227.4
(e) Income Tax Assets (net)	280.56	219.
(f) Other Non-current Assets	24.85	26.1
Total Non - Current Assets	8,170.06	8,670.
(2) Current Assets		
(a) Inventories		6.0
(b) Financial Assets		0.1
(i) Trade Receivables	281.15	392.
(ii) Cash and Cash Equivalents	837.87	241.4
(c) Current Tax Assets (Net)	057.07	241.
(iv) Other financial asset	55.46	15.3
	93.95	
(c) Other Current Assets Total Current Assets	1,268.43	81.3
Total Current Assets	1,208.45	151.4
TOTAL ASSETS	9,438.49	9,408.3
EQUITY AND LIABILITIES Equity (a) Equity Share capital	6,103.06	6,103.0
(b) Other Equity	1,617.31	960.9
Total Equity	7,720.37	7,064.0
LIABILITIES		
(1) Non-current Liabilities	The second s	
(a) Financial Liabilities	1 - 2 - 5 - 5 - 1 - 1 - 2	
(i) Borrowings	A 100 A	600.0
(ii) Other financial liabilities	69.88	66.1
(b) Other Non Current Liabilities	28.35	32.1
(c) Provisions	94.94	88.5
Total Non - Current Liabilities	193.17	786.8
(2) Current Liabilities	and the second	
(2) Current Liabilities (a) Financial Liabilities		
(2) Current Liabilities (a) Financial Liabilities (i) Borrowings		
(2) Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables		
 (2) Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables (a) Total outstanding dues of Micro and Small Enterprises 	15.46	15.5
 (2) Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables (a) Total outstanding dues of Micro and Small Enterprises (b) Total outstanding dues other than above 	125.05	191.1
 (2) Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables (a) Total outstanding dues of Micro and Small Enterprises (b) Total outstanding dues other than above (iii) Other financial liabilities 	125.05 361.31	191.1 403.9
 (2) Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables (a) Total outstanding dues of Micro and Small Enterprises (b) Total outstanding dues other than above (iii) Other financial liabilities (b) Other Current Liabilities 	125.05 361.31 192.16	191.1 403.9 118.1
 (2) Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables (a) Total outstanding dues of Micro and Small Enterprises (b) Total outstanding dues other than above (iii) Other financial liabilities (b) Other Current Liabilities (c) Provisions 	125.05 361.31 192.16 830.98	191.1 403.5 118.1 828.7
 (2) Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade payables (a) Total outstanding dues of Micro and Small Enterprises (b) Total outstanding dues other than above (iii) Other financial liabilities (b) Other Current Liabilities 	125.05 361.31 192.16	191. 403.9 118.

ZENOTECH LABORATORIES LIMITED CIN: L27100TG1989PLC010122 Survey No.250-252, Turkapally (V), Shameerpet (M), Hyderabad - 500078 Phone:+91.40.23480430 / 35 www.zenotechlab.com



Zenotech Laboratories Limited Standalone Cash flow statement for the Period ended September 30, 2022

Rs in Lakhs

	For the Period ended 30 September 2022	For the Year ended 31 March 2022
A. Cash flows from operating activities		
Loss before taxation	908.84	990.13
Adjustments for:		
Depreciation and amortisation	359.13	697.35
Amounts written back		(7.79)
Unrealised foreign exchange loss, net		0.27
Interest expenses	11.22	121.52
Interest income	(8.93)	(9.86)
Exceptional items		
Operating cash flows before working capital changes	1,270.26	1,791.62
Changes in Working Capital:		
(Increase)/ decrease in trade receivables	111.67	(12.50)
(Increase)/ decrease in inventories	6.08	0.11
(Decrease)/ increase in trade payables	(66.11)	22.22
(Increase)/ decrease in other financial assets	(39.71)	(1.61)
(Increase)/ decrease incurrent non financial assets	(00.1.1)	(1.01)
(Increase)/ decrease in non-current financial assets	(33.21)	
(Increase)/ decrease in non-current assets	-	(0.00)
(Increase)/ decrease in other current assets	(12.61)	6.83
(Decrease)/ increase in provisions for non current liabilities	9.17	9.15
(Decrease)/ increase in provisions for current liabilities	2.21	(11.72)
(Decrease)/ increase in other financial liabilities	(42.67)	55.60
(Decrease)/ increase in other current liabilities	74.00	7.44
Cash used in operations	1,279.07	1,867.14
Income taxes paid/ TDS (net)	(60.86)	(100.40)
Net cash used in operating activities (A)	1,218.21	1,766.74
ner oddir doed in operating dournee (r)	1,210,21	11.00.14
B.Cash flows from investing activities		
Payment for Purchase of property plant equipment		
(Including Capital advance & Work in Progress)	(19.52)	(193.75)
Deposits towards margin money		
Interest income received	8.93	9.86
Net cash provided by/ (used in) investing activities	(10.59)	(183.89)
C. Cash flows from financing activities		
Proceeds from borrowings, net		
Repayment of borrowings	(600.00)	(1,465.62)
Interest paid	(11.22)	(1,403.02) (121.52)
Net cash provided by financing activities (C)	(611.22)	(1,587.14)
wer cash provided by mancing activities (c)	(011.22)	(1,507.14)
Net Increase/ (decrease) in cash and cash equivalents during the year(A+B+C)	596.40	(4.29)
Cash and cash equivalents at the beginning of the year	241.48	245.77
Cash and cash equivalents at the end of the year	837.87	241.48
		NO CON



Notes:

- 1. The above financial results for the quarter ended September 30, 2022 have been reviewed by the Audit Committee meeting held on 28th October, 2022 and approved by the Board of Directors of the Company at their meeting held on the same day and have undergone a 'limited review' by the Statutory Auditors of the Company.
- These financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India.
- 3. Majority of the matters relating to several financial and non-financial irregularities pertaining to period prior to November 12, 2011 were abated/settled. Accordingly, based on the steps taken by the Company and evidence available so far, the Company believes that the financial impact if any, with respect to those legacy matters on the results of the Company is not material.
- 4. The Company's overseas subsidiaries namely Zenotech Farmaceutica Do Brasil Ltda (Zenotech-Brazil) and Zenotech Inc (Zenotech-USA) were defunct and reported as cancelled/revoked respectively based on the Registration Cancellation certificate dated 8th June, 2022 and Long Form Standing certificate dated 15th June, 2022 respectively, received from concerned authorities. Accordingly, the Company is of the view that it does not have subsidiaries, joint ventures and associates within the definition of Ind AS 110 and hence no longer CFS is applicable.
- 5. The financial results have been prepared on a going concern basis, considering that the Company is well placed to meet the cash burn requirements in the coming periods.
- 6. Other operating income relates to rentals for the Biotech facility and equipment leased to Sun Pharmaceutical Industries Limited for R&D activities.
- 7. The Company has only one segment, i.e. Pharmaceuticals.
- 8. Figures for previous period/ year have been regrouped to conform to the current period presentation.

By Order of the Board

DIN: 01219312

Place: New Delhi Date: 28-October-2022